Inflarx N V (IFRX) Return on Assets ROA from the fourth quarter of 2025 to fourth quarter of 2024 and for the year 2025, Average High and Low, Fundamental Ratios from Dec 31 2025 to Jun 30 2024 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Inflarx N V  (NASDAQ: IFRX)


Inflarx N V's ROA from the fourth quarter of 2025 to the fourth quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Inflarx N V's ROA in the fourth quarter of 2025?
Inflarx N V recorded a cumulative net loss of $-67 million during 12 months ending in the fourth quarter of 2025, resulting in a negative return on assets (ROA) of -111.59%.

However, within the Healthcare sector 792 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the third quarter of 2025 from to 4890.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Dec 31 2025)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Jun 30 2024)
II. Quarter
Y / Y Total Assets Change -23.19 % -39.35 % -50.86 % -50.86 % -36.03 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million -67 -31 -79 -63 -72
Return On Assets (TTM) -111.59 % -48.07 % -105.65 % -69.32 % -67.51 %
IFRX's Total Ranking # 4890 # # # # 4961
Total Assets (TTM) in million 60 60 60 60 79
Seq. Total Assets Change 0 % 0 % 0 % -23.19 % -21.04 %
Seq. Net Income Change - - - - -

IFRX's 5 Years Annual ROA >> Back to IFRX Management Effectiveness >> Compare IFRX ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 363
Sector # 793
Overall # 4849

Return On Assets Statistics
High Average Low
-19.32 %
-44.17 %
-82.65 %
(Dec 31 2018)   (Dec 31 2025)



  News about Inflarx N V Return on Assets ROA

InflaRx's Game-Changing Announcement: Unveiling the Future of Anti-Inflammatory Therapeutics

1. Article for :
InflaRx, a pioneering biopharmaceutical company focused on developing anti-inflammatory therapeutics targeting the complement system, is set to make a significant announcement concerning its upcoming development plans for a potential game-changer, INF904. Alongside this, the company will release its much-awaited financial and operating results for the fourth quarter and full year of 2023. The details will be presented during a conference call on March 21, 2024, providing a platform for InflaRx to showcase their progress and strategic vision.
INF904, an orally available C5aR inhibitor, has generated considerable excitement in the pharmaceutical industry due to its potential to serve as a best-in-class treatment. By specifically targeting the complement system, InflaRx aims to revolutionize the field of anti-inflammatory therapies. The upcoming announcement regarding the company s development plans for INF904 will shed light on the specific path and objectives for this innovative drug candidate.



Financial Statements
Inflarx N V's Assets $ 60 million IFRX's Balance sheet
Inflarx N V's Income $ -51 million Quarterly IFRX's Income Statement
IFRX's Income by Division See IFRX's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025		 (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2020)
FY 2020
Y / Y Total Assets Change -23.19 % -36.03 % 7.25 % 6.3 % -20.96 %
Total Assets in million 60 79 123 115 108
Y / Y Net Income Change - - - - -
Net Income in million -51 -50 -48 -33 -39
Annual Return On Assets -84.56 % -63.34 % -38.85 % -28.79 % -35.94 %

IFRX's 5 Years Annual ROA >> Back to IFRX Management Effectiveness >> Compare IFRX ROA to its Competitors



More Return On Assets Ratios
IFRX's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
IFRX's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for IFRX's Competitors
Subscribers only: Roa for Inflarx N V's Suppliers
Subscribers only: Return On Assets for IFRX's Customers

You may also want to know
IFRX's Roi IFRX's Inventory Turnover Ratio IFRX's Growth Rates IFRX's Dividend Comparisons
IFRX's Profitability Ratios IFRX's Asset Turnover Ratio IFRX's Dividend Growth
IFRX's Roe IFRX's Valuation Ratios IFRX's Financial Strength Ratios IFRX's Dividend Payout Ratio



Companies with similar Return On Assets at Dec 31 2025, within Healthcare Sector ROA

Date modified: 2026-07-07T11:32:40+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.